Randomized placebo-controlled dose-ranging and pharmacodynamics study of roxadustat (FG-4592) to treat anemia in nondialysis-dependent chronic kidney …
A Besarab, R Provenzano, J Hertel… - Nephrology Dialysis …, 2015 - academic.oup.com
Abstract Background Roxadustat (FG-4592) is an oral hypoxia-inducible factor prolyl
hydroxylase inhibitor that stimulates erythropoiesis. This Phase 2a study tested efficacy (Hb …
hydroxylase inhibitor that stimulates erythropoiesis. This Phase 2a study tested efficacy (Hb …
Roxadustat for the treatment of anemia in chronic kidney disease patients not on dialysis: a phase 3, randomized, double-blind, placebo-controlled study (ALPS)
E Shutov, W Sułowicz, C Esposito… - Nephrology Dialysis …, 2021 - academic.oup.com
Background Roxadustat is an orally active hypoxia-inducible factor prolyl hydroxylase
inhibitor for the treatment of chronic kidney disease (CKD) anemia. Methods This Phase 3 …
inhibitor for the treatment of chronic kidney disease (CKD) anemia. Methods This Phase 3 …
[HTML][HTML] Short-term effect of low-dose roxadustat combined with erythropoiesis-stimulating agent treatment for erythropoietin-resistant anemia in patients undergoing …
Q Xu, J Huang, Q Liu, X Wang, H Liu, Y Song… - Frontiers in …, 2024 - frontiersin.org
Background Erythropoietin resistance is present in some patients with chronic kidney
disease, especially in those undergoing hemodialysis, and is often treated using roxadustat …
disease, especially in those undergoing hemodialysis, and is often treated using roxadustat …
[HTML][HTML] RETRACTED: Pooled Analysis of Roxadustat for Anemia in Patients With Kidney Failure Incident to Dialysis
R Provenzano, S Fishbane, L Szczech, R Leong… - 2021 - Elsevier
Introduction Erythropoiesis-stimulating agents are associated with increased cardiovascular
risk when higher doses are used toward higher hematocrit targets. Patients new to dialysis …
risk when higher doses are used toward higher hematocrit targets. Patients new to dialysis …
[HTML][HTML] Roxadustat for the treatment of anemia in patients with chronic kidney diseases: a meta-analysis
L Zhang, J Hou, J Li, SS Su, S Xue - Aging (Albany NY), 2021 - ncbi.nlm.nih.gov
Background: Anemia is a common complication of chronic kidney disease (CKD). Treating
renal anemia with erythropoiesis-stimulating agents (ESAs) or erythropoietin analogs is …
renal anemia with erythropoiesis-stimulating agents (ESAs) or erythropoietin analogs is …
Roxadustat for treating anemia in patients with CKD not on dialysis: results from a randomized phase 3 study
S Fishbane, MA El-Shahawy… - Journal of the …, 2021 - journals.lww.com
Background Current anemia therapies for patients with non–dialysis-dependent CKD may
require injection and medical visits. Roxadustat, an oral hypoxia-inducible factor prolyl …
require injection and medical visits. Roxadustat, an oral hypoxia-inducible factor prolyl …
A prospective, self-controlled pilot study of the efficacy of roxadustat for erythropoietin hyporesponsiveness in patients requiring chronic ambulatory peritoneal dialysis
J Chen, Z Li, H Zhang, J Hu, J Wang, H Zhou… - Journal of Renal …, 2022 - Elsevier
Objectives The present study aimed to explore the efficacy and safety of roxadustat in
patients with renal anemia and erythropoietin (EPO) hyporesponsive who are receiving …
patients with renal anemia and erythropoietin (EPO) hyporesponsive who are receiving …
Treatment of renal anemia in patients with hemodialysis using hypoxia-inducible factor (HIF) stabilizer, roxadustat: a short-term clinical study
A Mima, Y Horii - in vivo, 2022 - iv.iiarjournals.org
Background/Aim: Renal anemia is a major complication in patients with chronic kidney
disease (CKD) and hemodialysis, increasing morbidity and mortality. Roxadustat is a novel …
disease (CKD) and hemodialysis, increasing morbidity and mortality. Roxadustat is a novel …
[HTML][HTML] Roxadustat for anemia in patients with kidney disease not receiving dialysis
N Chen, C Hao, X Peng, H Lin, A Yin… - … England Journal of …, 2019 - Mass Medical Soc
Abstract Background Roxadustat (FG-4592) is an oral inhibitor of hypoxia-inducible factor
(HIF) prolyl hydroxylase that stimulates erythropoiesis and regulates iron metabolism. In …
(HIF) prolyl hydroxylase that stimulates erythropoiesis and regulates iron metabolism. In …
Roxadustat for dialysis patients with erythropoietin hypo-responsiveness: a single-center, prospective investigation
Y Zhou, X Chen, Y Zhang, J Lou, H Yuan - Internal and Emergency …, 2021 - Springer
Dialysis patients with erythropoietin hypo-responsiveness suffered from refractory anemia.
Roxadustat reversibly binds and inhibits hypoxia-inducible factor-prolyl hydroxylase (HIF …
Roxadustat reversibly binds and inhibits hypoxia-inducible factor-prolyl hydroxylase (HIF …